2024-01-17 11:00
(46 d 15:56 ago)

Posting: # 23829
Views: 496

 Subject effect justification [General Sta­tis­tics]

We have performed a bioequivalence study which passed the acceptance criteria. However there is a subject (sequence) effect for for ln-transformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-∞. How this can be justified that doesn't affect the study results?:confused::confused:

2024-01-17 13:30
(46 d 13:26 ago)

@ Dafni_C
Posting: # 23831
Views: 417

 Subject effect justification

Dear Dafni_C.

Just for clarification of the background.
You conducted an ANOVA (or mixed effects model) with the effects "treatment", "sequence" and "period" as well as the effect "subject(sequence)"?
And in your "ANOVA"-table the p-value of "subject(sequence)" was found to be statistically significant?

There are more qualified persons here, but ...
this indicates that the subjects in the trial were different people, so that normally would be expected to be "significant", right?

If you mean the "sequence" effect or something else, you may find the information available in the "Articles" (see header at the very top) helpful.

Best regards!
UA Flag
 Admin contact
22,919 posts in 4,807 threads, 1,641 registered users;
29 visitors (0 registered, 29 guests [including 9 identified bots]).
Forum time: 02:56 CET (Europe/Vienna)

The analysis of variance is not a mathematical theorem,
but rather a convenient method of arranging the arithmetic.    R.A. Fisher

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz